KEI Comments on NIH Proposed Exclusive Patent License to St. Louis University for Treatment and Prevention of Neuropathic Pain With P2Y14 Antagonists

On December 3, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) regarding the “Prospective Grant of Exclusive Patent License: Treatment and Prevention of Neuropathic… Continue Reading

KEI Comments on Proposed Exclusive License to Connectyx for Degenerative Retinal Disease Treatment

On November 6, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the, “Prospective Grant of an Exclusive Patent License: Development of a Direct Ocular Administered Formulation of Metformin for Use in Therapeutic Treatment… Continue Reading

KEI Sues NIH over Improper Withholding of Three FOIA Requests

On September 29, 2020, Knowledge Ecology International (KEI) filed a lawsuit against the National Institutes of Health (NIH) regarding three Freedom of Information Act (FOIA) requests filed by KEI. The complaint filed by KEI requests injunctive, declaratory, and other appropriate… Continue Reading

Upcoming Sept 30 – TACD Webinar: Controlled Digital Lending in a Pandemic

(Update: A video recording of the full event is available on our YouTube channel. For a copy of the Zoom chat during the event, please reach out to the contact email below.) On Wednesday September 30, 2020, the Transatlantic Consumer… Continue Reading

KEI and UACT Comments to NIH on Proposed Exclusive License to Connectyx

On Friday September 11, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Anti-CD56 as an Antibody-Drug Conjugate… Continue Reading

KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications

On September 2, 2020, Knowledge Ecology International (KEI) sent a letter to the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential failure by Moderna, Inc. to disclose federal funding in patents supported by BARDA. KEI requested information concerning… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to ONK Therapeutics

(Update: The NIH has provided a response to our comments on August 31, 2020) On August 28, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) “Prospective… Continue Reading

KEI Comments Regarding NIH Exclusive License to PreciThera

(Update: The NIH provided a response to our comments on August 24, 2020) On August 20, 2020, Knowledge Ecology International (KEI) submitted comments regarding the prospective grant of an exclusive license by the National Institutes of Health (NIH) to PreciThera,… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to Cytovia for CAR Technology

On August 14, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the NIH’s “Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3” (85 FR 45912). The… Continue Reading